Kate Coleman, PhD

As senior scientist at Yarrow, Kate is contributing to the discovery and characterization of antibody drug candidates for treating autoimmune disorders.

Prior to joining Yarrow, Kate was trained as a cell and molecular biologist, with a research background in cell cycle control and mechanisms regulating genome integrity. As a PhD student in the lab of Dr. Jean Cook, she studied the cell cycle transition from G1/S phase and its regulation by the E3 ubiquitin ligase CRL4Cdt2. She later joined the lab of Dr. Tony Huang as a postdoctoral fellow, focusing on the role of deubiquitylating enzymes (DUBs) in the replication stress response. In her most recent role as Principal Scientist at Concarlo Therapeutics, Kate developed cell-based assays to assess in vitro efficacy of small molecule therapeutic candidates targeting the cyclin-dependent kinase (Cdk) inhibitor p27.

Kate received her PhD in Genetics & Molecular Biology from the University of North Carolina at Chapel Hill and a BA in Biochemistry & Molecular Biology from Boston University.